ISD Immunotech is developing a first-in-class therapy to treat the most severe Systemic lupus erythematosus (SLE) patients.
ISD Immunotech has 1 recorded funding round in the Tech.eu database (amounts undisclosed). Based in Aarhus, Denmark; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-10-04 | Other |
| — |
| EIR Ventures,Novo Seeds |
| View deal → |
